Advanced drug uptake and retention for PAD treatment Patented biodegradable functionalized nanoparticles (f-NPs) from Advanced NanoTherapies and a cool coating process developed at Cleveland Clinic create a safer therapeutic option for Peripheral Artery Disease (PAD) patients through Sirolimus-coated angioplasty balloons. - Marwan Berrada-Sounni, CEO Our initial focus is on bringing a safer and more effective therapeutic option to patients with peripheral artery disease. In the future, our innovative drug-delivery platform can scale to help patients with coronary and peripheral in-stent restenosis, those who receive dialysis and many, many others. - Mehdi Shishehbor, DO, MPH, PhD While drug delivery using coated balloons is a well-established treatment strategy, our vision for using f-NP technology to address PAD represents a major advancement in drug-coated balloon (DCB) technology. - Vinod Labhasetwar, PhD Due to technically challenging requirements involved in delivering Sirolimus efficiently to a stenosed artery, Advanced NanoTherapies’ use of f-NP is truly innovative.

Need for safer PAD treatments

Paclitaxel based devices, the current drug used for treating PAD, has raised safety concerns, and Sirolimus based devices have replaced it as a safer, more effective treatment. However, to improve bioavailability, Sirolimus based devices need to be encapsulated and retained in the artery. This has proved to be problematic.

Better outcomes for
12 million people

Functionalized nanoparticles (f-NP) are employed to enable and improve uptake and retention of Sirolimus based devices in PAD patients. This allows approximately 12 million people with Peripheral Artery Disease an opportunity for better outcomes.

A path to a safer and more effective option

With the major advancement in drug-coated balloon (DCB) technology, the leadership team sat down and discussed their focus on bringing a better alternative to patients with Peripheral Artery Disease (PAD).

Leadership Team

CEO: Marwan Berrada-Sounni, MSc, MBA

A successful entrepreneur with extensive experience in cardiovascular and endovascular devices.

CMO: Mehdi Shishehbor, DO, MPH, PhD

Chief Medical Officer and President, Harrington Heart and Vascular Institute University Hospitals, Cleveland

Vinod Labhasetwar, PhD

Professor and Endowed Chair of Nanomedicine, Department of Biomedical Engineering at Cleveland Clinic Lerner Research

Achievements to Date

Advanced NanoTherapies is working closely with the FDA to achieve an early feasibility study and introduce its technology to human populations.

Efficient balloon-
to-tissue drug uptake

Sustained
controlled release

Drug interchangeability
and multi-drug delivery

No particle release
during handling